Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) shares fell 3.5% during trading on Friday . The company traded as low as $16.14 and last traded at $16.50. 11,425 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 208,577 shares. The stock had previously closed at $17.10.
Analysts Set New Price Targets
Several equities research analysts have recently commented on SION shares. Stifel Nicolaus assumed coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $32.00 target price for the company. TD Cowen began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating for the company. Finally, Guggenheim initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $45.00 target price on the stock.
Get Our Latest Analysis on SION
Sionna Therapeutics Stock Down 10.8 %
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
- Five stocks we like better than Sionna Therapeutics
- What is MarketRank™? How to Use it
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Profit From Value Investing
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What Are Dividend Challengers?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
